An Executive Playbook for AI in Regulated Industries

Regulated industries have exactly what agents need: enormous volumes of rule-bounded work, written procedures, and measured baselines. They also have accountability regimes that make careless deployment expensive. The result is not that regulated firms should move slowly, but that they should move in a specific order and build evidence as they go. This whitepaper sets out that playbook. It is general guidance, not legal or regulatory advice; obligations vary by sector and jurisdiction.

Where should regulated firms start?

With operational and documentation work where errors are visible and contained.

Layer	Examples	Agent role	Regulatory exposure
Internal operations	Reconciliation, document collection, case file assembly, scheduling	Acts within policy	Low; errors caught internally
Documentation and reporting	Regulatory report preparation, records assembly, completeness checks	Prepares; human attests	Low to moderate; attestation stays human
Customer service (non-advisory)	Status, administrative requests, scheduling	Acts within written policy	Moderate; disclosure and conduct rules apply
Decision support	Evidence gathering, checks against criteria, recommendation	Prepares; human decides	Moderate; oversight must be documented
Regulated decisions	Credit, coverage, eligibility, clinical, suitability	None or strictly bounded	High; human decision and explanation required

The sequence is deliberate: the first two layers build the platform, the evidence practices, and the organizational confidence that the later layers require, without exposing the firm to the consequences of an untested system making consequential decisions.

What must stay with accountable humans?

Decisions with regulatory consequence and the attestations that accompany them: credit and adverse action decisions, coverage determinations, suitability and advice, clinical judgments, regulatory filings and attestations, and anything a regulator expects a named individual to stand behind. Agents prepare the evidence, check completeness, apply written criteria, and recommend; a qualified person decides, and the record shows who.

Two design implications follow. The boundary must be enforced in the agent's permissions rather than in its instructions, because instructions can be manipulated and permissions cannot. And the record must show the human's engagement, not merely their approval click, which usually means capturing what was presented and what the reviewer changed.

What evidence do regulated deployments need?

Evidence is the deliverable, and it should be produced as the system is built rather than assembled before an examination.

Documented intended use. What the system does, in scope and out of scope, with a risk assessment proportionate to its role.

Validation before use. An evaluation set of real cases with acceptance criteria defined in advance, results retained. In validation-heavy sectors this is the artifact that satisfies the requirement; the AI evaluation explained for executives piece covers its construction.

Traceability. Attributable, contemporaneous records: what the agent received, what it produced, which version and configuration produced it, what the reviewer changed, and who approved. The AI observability explained for executives piece covers the instrumentation.

Human oversight records. Not just that review occurred, but what was reviewed and what resulted.

Change control. Prompts, tools, retrieval sources, and model versions under control, with revalidation triggers. This includes provider-initiated model updates, which are changes even though the firm did not make them. The model deprecation risk management guide covers the mechanics.

Access control and segregation. Per-agent identity, least privilege, and separation between preparation and approval.

How should existing frameworks be extended?

By extension, not duplication. Regulated firms already run model risk management, quality management, market conduct, or clinical governance frameworks depending on sector. Agents should be brought inside them, with agent-specific controls added where traditional frameworks have gaps:

Existing framework element	Agent-specific addition
Model inventory	Agents, including vendor-embedded AI
Validation	Evaluation sets on real cases; adversarial testing
Monitoring	Drift detection; exception and agreement rates
Change control	Prompts, tools, retrieval, and provider model versions
Access management	Non-human identities with per-tool permissions
Incident management	Agent kill switches; trace-based investigation
Third-party risk	Model providers; embedded AI in vendor products

A parallel AI governance structure creates two problems: the AI decisions are made with less rigor than equivalent non-AI decisions, and the firm has two sets of records to reconcile at examination. The executive guide to AI agent governance covers the structure being extended.

How should regulators be engaged?

Early, with a plan rather than a deployed system. The pattern that works across sectors: present the intended use, the risk classification, the governance and validation approach, and the human oversight arrangements before building; then return with evidence from supervised operation. Regulators respond very differently to a firm seeking to understand expectations than to one seeking retrospective approval for something already live.

Specific questions worth raising: whether the intended use falls within an existing regulatory category; what documentation the regulator expects for validation; how provider model updates should be handled; what disclosure is expected to customers or patients; and whether the firm's proposed oversight arrangement satisfies the requirement for human involvement.

What about third-party and vendor AI?

The exposure regulated firms most often miss. AI features appear inside vendor products the firm already uses, and they process regulated data without going through AI procurement. The controls: add AI questions to vendor reviews and renewals; inventory embedded AI as part of the model or system inventory; require contractual notice of AI feature additions and model changes; and assess data flows to vendors' own subprocessors. The questions your CISO will ask about AI guide covers the assessment questions.

How should autonomy be handled in regulated settings?

More conservatively than elsewhere, and explicitly. Ceilings sit lower: many action classes that would run autonomously in an unregulated firm keep permanent human approval because the regulatory expectation is a human decision. Within those ceilings, the same evidence-based progression applies: start with full review, release only where agreement rates and evaluation evidence are strong and the action is reversible and low-consequence, and withdraw immediately on incidents or drift. The how much autonomy should AI agents have guide covers the framework; in regulated settings the policy lines do more of the work than the evidence does.

What does the first year look like?

Quarter	Focus	Evidence produced
Q1	Intended-use classification; governance extension; platform with identity, gateway, tracing; first operational process specified	Risk classification; validation plan; specification
Q2	First agent in supervised production on internal operations; evaluation evidence; monitoring	Validation results; oversight records; incident log
Q3	Second agent on documentation or reporting preparation; regulator engagement on approach; internal audit review	Audit findings; regulator correspondence; updated framework
Q4	Autonomy released on low-consequence actions with evidence; third process specified; annual review of the framework	Autonomy decisions with evidence; framework review

The sequence deliberately avoids customer-facing and decision-adjacent work in year one, not because it is impossible but because the evidence practices should be proven on contained work first.

How does this differ across sectors?

The playbook holds; the emphasis shifts.

In financial services, model risk management is the natural home for agent governance, examiners ask about documentation and independent challenge, and the sharpest boundary is around credit and adverse action decisions. In healthcare and life sciences, the boundary is clinical judgment and the evidence expectation centers on validation and audit trails, with data protection obligations shaping deployment options. In insurance, unfair discrimination and market conduct requirements make fairness testing a release gate rather than a study. In utilities and critical infrastructure, the sharpest boundary is between information systems and operational technology, and security expectations exceed the commercial norm. In legal and accounting, professional duties of competence, confidentiality, and supervision apply to the work regardless of the tool.

What does not change: start on contained operational work, keep consequential decisions human, produce evidence as you build, extend existing frameworks, and engage the regulator with a plan.

What should the board see?

A quarterly view that connects the AI estate to the firm's regulatory position: the inventory by risk tier with the regulated activities each touches; validation status for systems in regulated processes; human oversight arrangements and any exceptions; incidents with regulatory implications; regulator interactions; third-party and embedded AI exposure; and the framework's currency against changing requirements. For regulated firms this reporting is not only good practice, it is part of the record that demonstrates the board discharged its oversight duty. The AI oversight and fiduciary duty piece covers why that record matters.

What are the failure modes?

Treating agents as unregulated productivity tools when they touch regulated activities. The most expensive mistake, usually discovered at examination.

Quality and compliance involved at deployment rather than design. Produces rebuilds.

No change control for provider model updates. A validated system quietly becomes an unvalidated one.

Audit trails retrofitted. Far harder under examination pressure than during the build.

Autonomy released on general evidence rather than per action class within policy lines.

Vendor-embedded AI unmanaged, because it never went through the AI process.

What should executives in regulated firms ask?

• For each agent, what is the documented intended use and risk classification?
• Which regulated activities does it touch, and who attests to the output?
• Could we produce the validation evidence and the trace for any case an examiner selects?
• What happens when our model provider updates a version we validated?
• Has the regulator been engaged on the approach, or will they see it first at examination?
• Which vendor products have added AI features since we last reviewed them?

How can FISTA Solutions help regulated firms?

FISTA Solutions builds AI agents for regulated environments with documented intended use, evaluation sets constructed as validation evidence, complete traceability, per-agent identity and segregation, change control covering provider model updates, and human decision boundaries enforced in permissions. Its AI enablement practice works with executive, compliance, quality, and audit functions to extend existing frameworks rather than build parallel ones. Since 2017, FISTA has delivered 150+ projects for 50+ companies across 12+ countries, with a 99.9% uptime record on production systems.

To scope a first deployment your compliance and audit functions will accept, talk to FISTA on WhatsApp, or read the private AI for regulated industries whitepaper for the deployment options.